RinLis®

RinLis®
Product Description

Insulin lispro. 
Dosage form: solution for subcutaneous and intravenous injections in 3 ml cartridges and disposable insulin pen. 

·         Widely used fast acting insulin analogue.
·         Characterised by reverse lysine and proline residues on amino acid sequence in the insulin amino acid chain. 
·         Fast absorption from subcutaneous injection sites. 
·         Onset of action after subcutaneous administration – in 15 minutes.
·         0.5-2.5 hours – maximum action. 
·         3-4 hours – duration of action.

 

Geropharm

  • RU
  • 2019
    On CPhI since
Specifications
  • Supplied from
    Russian Federation

Geropharm

  • RU
  • 2019
    On CPhI since

More Products from Geropharm

  • RinGlar®

    Product RinGlar®

    Insulin glargine. 

    Dosage form: solution for subcutaneous injections in 3 ml cartridges and pre-filled disposable insulin pen.

    ·         Long-acting basal insulin
    ·         Maintains normal physiologic concentration of basal (background) insulin
    ·         Most widely used basal insulin analogue. Is the reference product for all basal insulins.
    ·         Increased duration of action of insulin glargine is associated with subcutaneous microprecipitate generation from which small amounts of insulin glargine permanently release, which makes it possible to administer the product once a day.
    ·         Concentration: U100
    ·         Onset of action after subcutaneous administration – in 1 hour
    ·         29 hours – maximum action
    ·         24 hours – duration of action

  • RinLis®  Mix 25

    Product RinLis® Mix 25

    Insulin lispro biphasic 25.Dosage form: susupension for subcutaneous injections in 3 ml cartridges and pre-filled disposable insulin pen.

    ·         Has fast and predictable effect and the elimination typical for physiologic insulin secretion.
    ·         Prandial component ensures faster and more predictable onset of action as well as fast elimination peculiar to physiologic insulin secretion, extended component ensures smooth peakless profile of basal insulin.
    ·         Onset of action after subcutaneous administration – in 15 minutes
    ·         0.5-2.5 hours – maximum action
    ·         Up to 15 hours – duration of action 


  • Rinsulin® R

    Product Rinsulin® R

    insulin human soluble
    Dosage form: solution for injections in 10 ml vials, 3 ml cartridges and pre-filled disposable insulin pen. 

    ·         Onset of action after subcutaneous administration – up to 30 min
    ·         Maximum action – 3 hours in average
    ·         Duration of action – 8 hours in average

  • Rinsulin® NPH

    Product Rinsulin® NPH

    Insulin human isophane (recombinant)Dosage form: suspension for subcutaneous injections in 10 ml vials, 3 ml cartridges and pre-filled disposable insulin pen.

    GEROPHARM’s insulin isophane is available on market since 2011.

    ·         Onset of action after subcutaneous administration – 1.5 hours
    ·         Maximum action – 4-12 hours in average
    ·         Duration of action – 24 hours in average
  • Cortexin®

    Product Cortexin®

    Neuropeptide, which ensures that the nervous tissue is protected and restored in case of various nervous system diseases.Is used within the comprehensive treatment of:

    • cerebral circulation disorder;• TBI and its consequences;
    • encephalopathies of various genesis;
    • cognitive disorders (dysfunction of memory and mentality);
    • acute and chronic encephalitis and encephalomyelitis;
    •epilepsy •asthenic conditions (suprasegmental autonomic disorders);
    •reduction in learning capacity; 
    •psychomotor and speech retardation in children;
    •various forms of infantile cerebral paralysis (ICP).
  • Retinalamin®

    Product Retinalamin®

    Drug product that stimulates retina regeneration.
    It is used in complex therapy with:

    •compensated primary open-angle glaucoma; •diabetic retinopathy; 
    •posttraumatic and postinflammatory, central dystrophy of retina; 
    •central dystrophy of retina; 
    •myopia (as a part of complex therapy); 
    •central and peripheral tapetoretina; 
    •abiotrophy; 
    •rhegmatogenous and traumatic retinal; 
    •detachment (rehabilitation postoperative period as a part of complex therapy); 

Geropharm resources

Recommended products